Are Serotonergic System Genes Associated to Smoking Cessation Therapy Success in Addition to CYP2A6?

Abstract

Despite progress made in the treatment of tobacco dependence, currently available treatments are effective for only a fraction of smokers. The aim of this study was to evaluate the association between the effectiveness of treatment with nicotine or bupropion in heavy smokers (n=70), and 6 candidate polymorphisms in CYP2A6, 5-HTT and HTR2A genes. Analysis revealed a significant association between “favourable” genotype combination carriers (CYP2A6 “slow metabolizer” or 5HTT L-allele or HTR2A-1438GG) and nicotine treatment outcome (OR=2.69, 95% CI=1.28–5.64). Genetic variations in CYP2A6 gene or genotypes associated with reduced synaptic serotonin activity may influence the success of smoking cessation treatment.

Key words

nicotine - bupropion - CYP2A6 - 5-HTT LPR - HTR2A-1438A>G

• References

• 1 Fiore MC. US public health service clinical practice guideline: treating tobacco use and dependence. Respir Care 2000; 45: 1200-1262
• 2 Gold PB, Rubey RN, Harvey RT. Naturalistic, self-assignment comparative trial of bupropion SR, a nicotine patch, or both for smoking cessation treatment in primary care. Am J Addict 2002; 11: 315-331
• 3 Fiore MC, Jaen CR. A clinical blueprint to accelerate the elimination of tobacco use. JAMA 2008; 299: 2083-2085
• 4 Kortmann GL, Dobler CJ, Bizarro L et al. Pharmacogenetics of smoking cessation therapy. Am J Med Genet B Neuropsychiatr Genet 2010; 153: 17-28
• 5 King DP, Paciga S, Pickering E et al. Smoking cessation pharmacogenetics: analysis of varenicline and bupropion in placebo-controlled clinical trials. Neuropsychopharmacology 2012; 37: 641-650
• 6 Swan GE, Benowitz NL, Lessov CN et al. Nicotine metabolism: the impact of CYP2A6 on estimates of additive genetic influence. Pharmacogenet Genomics 2005; 15: 115-125
• 7 Mwenifumbo JC, Tyndale RF. Molecular genetics of nicotine metabolism. Handb Exp Pharmacol 2009; 192: 235-259
• 8 O’Gara C, Knight J, Stapleton J et al. Association of the serotonin transporter gene, neuroticism and smoking behaviours. J Hum Genet 2008; 53: 239-246
• 9 Borrelli B, Niaura R, Keuthen NJ et al. Development of major depressive disorder during smoking-cessation treatment. J Clin Psychiatry 1996; 57: 534-538
• 10 Breslau N, Chilcoat H, Schultz LR. Anxiety disorders and the emergence of sex differences in major depression. J Gend Specif Med 1998; 1: 33-39
• 11 Lerman C, Shields PG, Audrain J et al. The role of the serotonin transporter gene in cigarette smoking. Cancer Epidemiol Biomarkers Prev 1998; 7: 253-255
• 12 Mihailescu S, Palomero-Rivero M, Meade-Huerta P et al. Effects of nicotine and mecamylamine on rat dorsal raphe neurons. Eur J Pharmacol 1998; 360: 31-36
• 13 Tyndale RF. Genetics of alcohol and tobacco use in humans. Ann Med 2003; 35: 94-121
• 14 Munafo M, Clark T, Johnstone E et al. The genetic basis for smoking behavior: a systematic review and meta-analysis. Nicotine Tob Res 2004; 6: 583-597
• 15 Quaak M, van Schayck CP, Knaapen AM et al. Genetic variation as a predictor of smoking cessation success. A promising preventive and intervention tool for chronic respiratory diseases?. Eur Respir J 2009; 33: 468-480
• 16 Illi A, Poutanen O, Setala-Soikkeli E et al. Is 5-HTTLPR linked to the response of selective serotonin reuptake inhibitors in MDD?. Eur Arch Psychiatry Clin Neurosci 2011; 261: 95-102
• 17 Dreimuller N, Tadic A, Dragicevic A et al. The serotonin transporter promoter polymorphism (5-HTTLPR) affects the relation between antidepressant serum concentrations and effectiveness in major depression. Pharmacopsychiatry 2012; 45: 108-113
• 18 Verde Z, Santiago C, Rodriguez Gonzalez-Moro JM et al. ‘Smoking genes’: a genetic association study. PLoS One 2011; 6: e26668
• 19 Lerman CE, Schnoll RA, Munafo MR. Genetics and smoking cessation improving outcomes in smokers at risk. Am J Prev Med 2007; 33 (6 Suppl) S398-S405
• 20 Cervilla JA, Rivera M, Molina E et al. PREDICT Study Core Group . The 5-HTTLPR s/s genotype at the serotonin transporter gene (SLC6A4) increases the risk for depression in a large cohort of primary care attendees: the PREDICT-gene study. Am J Med Genet B: Neuropsychiatr Genet 2006; 141: 912-917
• 21 Quaak M, van Schayck CP, Postma DS et al. Genetic variants in the serotonin transporter influence the efficacy of bupropion and nortriptyline in smoking cessation. Addiction 2012 Jan 107: 178-187
• 22 Lerman C. Preclinical data elucidate molecular and neural mechanisms of perinatal nicotine effects on neurodevelopment and behavior: translational opportunities and implications. Neuropsychopharmacology 2010; 35: 2322-2323
• 23 Christiansen L, Tan Q, Iachina M et al. Candidate gene polymorphisms in the serotonergic pathway: influence on depression symptomatology in an elderly population. Biol Psychiatry 2007; 61: 223-230
• 24 Malaiyandi V, Lerman C, Benowitz NL et al. Impact of CYP2A6 genotype on pretreatment smoking behaviour and nicotine levels from and usage of nicotine replacement therapy. Mol Psychiatry 2006; 11: 400-409
• 25 Seth P, Cheeta S, Tucci S et al. Nicotinic-serotonergic interactions in brain and behaviour. Pharmacol Biochem Behav 2002; 71: 795-805
• 26 McMahon FJ, Buervenich S, Charney D et al. Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment. Am J Hum Genet 2006; 78: 804-814
• 27 Attia J, Ioannidis JP, Thakkinstian A et al. How to use an article about genetic association: B: Are the results of the study valid?. JAMA 2009; 301: 191-197